ranolazine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
2359 95635-55-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • ranolazine hydrochloride
  • ranolazine
  • ranexa
  • renexa
  • ranolazine HCl
An acetanilide and piperazine derivative that functions as a SODIUM CHANNEL BLOCKER and prevents the release of enzymes during MYOCARDIAL ISCHEMIA. It is used in the treatment of ANGINA PECTORIS.
  • Molecular weight: 427.55
  • Formula: C24H33N3O4
  • CLOGP: 1.01
  • LIPINSKI: 0
  • HAC: 7
  • HDO: 2
  • TPSA: 74.27
  • ALOGS: -3.59
  • ROTB: 9

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
1.50 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 6 % Benet LZ, Broccatelli F, Oprea TI
BA (Bioavailability) 42.50 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 1.20 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 9.50 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.38 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 1.80 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Jan. 27, 2006 FDA GILEAD

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Electrocardiogram QT prolonged 125.91 18.03 82 7509 59448 63421983
Bradycardia 110.55 18.03 82 7509 73145 63408286
Chest pain 89.22 18.03 119 7472 215840 63265591
Tonic clonic movements 65.95 18.03 18 7573 1417 63480014
Torsade de pointes 65.60 18.03 32 7559 13319 63468112
Dizziness 62.69 18.03 150 7441 429775 63051656
Angina pectoris 62.47 18.03 41 7550 30037 63451394
Drug interaction 55.92 18.03 99 7492 229032 63252399
Chromaturia 45.33 18.03 27 7564 16690 63464741
Stent placement 45.25 18.03 17 7574 3738 63477693
Pulseless electrical activity 42.96 18.03 20 7571 7501 63473930
Coronary artery disease 41.65 18.03 33 7558 32344 63449087
Cardiac arrest 41.21 18.03 53 7538 92492 63388939
Hyperkalaemia 37.55 18.03 39 7552 54164 63427267
Syncope 35.64 18.03 56 7535 117329 63364102
Sinus bradycardia 35.59 18.03 22 7569 14529 63466902
Catheterisation cardiac 35.14 18.03 15 7576 4588 63476843
Hypotension 34.23 18.03 90 7501 272514 63208917
Serum serotonin increased 32.61 18.03 7 7584 198 63481233
Urinary straining 29.18 18.03 5 7586 40 63481391
Therapeutic response unexpected 28.24 18.03 21 7570 18738 63462693
Product residue present 27.22 18.03 12 7579 3967 63477464
Ventricular tachycardia 27.06 18.03 21 7570 19958 63461473
Pulmonary oedema 25.31 18.03 32 7559 54841 63426590
Hypersensitivity pneumonitis 24.84 18.03 10 7581 2640 63478791
Dyspnoea 24.17 18.03 148 7443 661165 62820266
Myocardial infarction 24.09 18.03 43 7548 99850 63381581
Left ventricular hypertrophy 23.90 18.03 12 7579 5303 63476128
Hypoglycaemia 23.04 18.03 32 7559 60033 63421398
Circumoral swelling 22.82 18.03 4 7587 37 63481394
Death 22.18 18.03 96 7495 374285 63107146
Nodal rhythm 21.39 18.03 8 7583 1735 63479696
Autonomic nervous system imbalance 20.91 18.03 9 7582 2809 63478622
Sinus arrest 20.53 18.03 8 7583 1941 63479490
Myopathy 20.22 18.03 14 7577 11177 63470254
Joint swelling 20.19 18.03 7 7584 327659 63153772
Infusion related reaction 19.56 18.03 3 7588 245518 63235913
Coronary artery bypass 19.01 18.03 8 7583 2361 63479070

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Chest pain 154.52 18.63 184 9663 126578 34820506
Dizziness 149.76 18.63 240 9607 218281 34728803
Syncope 86.24 18.63 117 9730 91334 34855750
Angina pectoris 79.79 18.63 68 9779 31295 34915789
Drug interaction 78.97 18.63 187 9660 225759 34721325
Stent placement 59.74 18.63 29 9818 5049 34942035
Coronary artery disease 55.16 18.63 68 9779 48237 34898847
Dyspnoea 54.02 18.63 229 9618 376553 34570531
Rhabdomyolysis 45.19 18.63 74 9773 68089 34878995
Chromaturia 42.14 18.63 34 9813 14486 34932598
Bradycardia 39.74 18.63 74 9773 75344 34871740
Death 36.98 18.63 214 9633 397835 34549249
Electrocardiogram QT prolonged 36.42 18.63 51 9796 40901 34906183
Hypotension 34.18 18.63 138 9709 221511 34725573
Cardiac failure congestive 33.46 18.63 73 9774 83197 34863887
Myocardial infarction 32.57 18.63 91 9756 120994 34826090
Product residue present 27.32 18.63 14 9833 2732 34944352
Heart valve stenosis 27.10 18.63 6 9841 80 34947004
Cardiac failure 26.95 18.63 71 9776 91177 34855907
Ventricular tachycardia 26.50 18.63 35 9812 26544 34920540
Presyncope 25.31 18.63 29 9818 19030 34928054
Tremor 24.12 18.63 64 9783 82523 34864561
Angina unstable 23.15 18.63 22 9825 11631 34935453
Vertigo 22.99 18.63 32 9815 25504 34921580
Asthenia 22.10 18.63 131 9716 245120 34701964
Keratolysis exfoliativa acquired 21.53 18.63 3 9844 0 34947084
Myocardial necrosis 20.67 18.63 6 9841 247 34946837
Aortic bruit 20.67 18.63 6 9841 247 34946837
Respiratory tract haemorrhage 20.39 18.63 9 9838 1261 34945823
Loss of consciousness 20.14 18.63 60 9787 82607 34864477
Myopathy toxic 19.40 18.63 7 9840 579 34946505

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Chest pain 196.36 16.13 250 14405 282054 79447679
Dizziness 157.64 16.13 317 14338 526124 79203609
Electrocardiogram QT prolonged 134.27 16.13 120 14535 90266 79639467
Drug interaction 131.30 16.13 256 14399 414927 79314806
Bradycardia 123.59 16.13 138 14517 135419 79594314
Angina pectoris 119.78 16.13 89 14566 51643 79678090
Syncope 109.15 16.13 149 14506 179300 79550433
Stent placement 101.57 16.13 40 14615 6480 79723253
Coronary artery disease 91.44 16.13 84 14571 65390 79664343
Hypotension 65.14 16.13 203 14452 440114 79289619
Rhabdomyolysis 63.17 16.13 86 14569 103045 79626688
Chromaturia 61.15 16.13 45 14610 25701 79704032
Dyspnoea 60.30 16.13 313 14342 856712 78873021
Death 59.38 16.13 233 14422 566281 79163452
Myocardial infarction 56.10 16.13 112 14543 184017 79545716
Tonic clonic movements 54.03 16.13 19 14636 2245 79727488
Torsade de pointes 50.99 16.13 36 14619 19276 79710457
Gastrointestinal haemorrhage 46.36 16.13 91 14564 147628 79582105
Cardiac arrest 44.61 16.13 98 14557 171998 79557735
Cardiac failure congestive 43.81 16.13 87 14568 142315 79587418
Catheterisation cardiac 42.92 16.13 21 14634 5707 79724026
Sinus bradycardia 40.40 16.13 35 14620 25212 79704521
Angina unstable 39.49 16.13 29 14626 16498 79713235
Ventricular tachycardia 38.67 16.13 43 14612 41892 79687841
Pulseless electrical activity 36.47 16.13 26 14629 14134 79715599
Hypoglycaemia 36.09 16.13 66 14589 101528 79628205
Coronary artery bypass 36.02 16.13 19 14636 6043 79723690
Presyncope 34.30 16.13 40 14615 41014 79688719
Infusion related reaction 31.43 16.13 3 14652 230234 79499499
Asthenia 31.16 16.13 180 14475 511509 79218224
Coronary arterial stent insertion 30.50 16.13 17 14638 6027 79723706
Fall 29.33 16.13 171 14484 487458 79242275
Rheumatoid arthritis 27.71 16.13 3 14652 208467 79521266
Product residue present 26.60 16.13 13 14642 3523 79726210
Drug ineffective 26.36 16.13 106 14549 1080807 78648926
Serum serotonin increased 26.30 16.13 7 14648 323 79729410
Urinary straining 26.12 16.13 5 14650 49 79729684
Intentional overdose 25.93 16.13 59 14596 105901 79623832
Heart valve stenosis 25.31 16.13 6 14649 172 79729561
Pyrexia 24.05 16.13 56 14599 678653 79051080
Hyperkalaemia 24.00 16.13 60 14595 114338 79615395
Rectal haemorrhage 23.91 16.13 47 14608 76253 79653480
Wrong technique in product usage process 23.75 16.13 46 14609 73829 79655904
Acute myocardial infarction 23.59 16.13 47 14608 76989 79652744
Nasopharyngitis 22.90 16.13 9 14646 253872 79475861
Aortic bruit 22.46 16.13 6 14649 281 79729452
Myopathy 22.33 16.13 23 14632 20540 79709193
Labelled drug-drug interaction medication error 21.54 16.13 26 14629 27624 79702109
Cardiac failure 21.53 16.13 70 14585 154772 79574961
Treatment failure 21.32 16.13 3 14652 170483 79559250
Respiratory tract haemorrhage 20.96 16.13 9 14646 1814 79727919
Circumoral swelling 20.82 16.13 4 14651 40 79729693
Bundle branch block left 20.55 16.13 17 14638 11496 79718237
Atrial fibrillation 20.30 16.13 81 14574 197805 79531928
Musculoskeletal stiffness 19.85 16.13 4 14651 175004 79554729
Tremor 19.39 16.13 72 14583 170011 79559722
Myocardial necrosis 19.16 16.13 6 14649 495 79729238
Nodal rhythm 19.12 16.13 10 14645 3125 79726608
Hypotonic urinary bladder 18.64 16.13 4 14651 72 79729661
Melaena 18.46 16.13 37 14618 60853 79668880
Anaemia 18.26 16.13 142 14513 444873 79284860
Loss of consciousness 18.24 16.13 70 14585 167873 79561860
Cardiac pacemaker insertion 18.08 16.13 12 14643 5810 79723923
Therapeutic product effect decreased 18.06 16.13 4 14651 163859 79565874
Dysarthria 18.06 16.13 39 14616 67583 79662150
Myopathy toxic 18.03 16.13 7 14648 1091 79728642
Chest discomfort 17.93 16.13 61 14594 137983 79591750
Keratolysis exfoliativa acquired 17.79 16.13 3 14652 13 79729720
Gravitational oedema 17.65 16.13 8 14647 1831 79727902
Hypersensitivity pneumonitis 17.47 16.13 10 14645 3729 79726004
Ventricular enlargement 16.92 16.13 6 14649 726 79729007
Confusional state 16.85 16.13 108 14547 317889 79411844
Enzyme inhibition 16.57 16.13 3 14652 21 79729712
Vertigo 16.38 16.13 38 14617 69044 79660689
Palatal oedema 16.24 16.13 7 14648 1424 79728309

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC C01EB18 CARDIOVASCULAR SYSTEM
CARDIAC THERAPY
OTHER CARDIAC PREPARATIONS
Other cardiac preparations
FDA EPC N0000175427 Anti-anginal
MeSH PA D002317 Cardiovascular Agents
MeSH PA D049990 Membrane Transport Modulators
MeSH PA D026941 Sodium Channel Blockers
FDA MoA N0000182137 Cytochrome P450 2D6 Inhibitors
FDA MoA N0000185503 P-Glycoprotein Inhibitors
FDA MoA N0000187061 Organic Cation Transporter 2 Inhibitors
FDA MoA N0000190114 Cytochrome P450 3A Inhibitors
CHEBI has role CHEBI:38070 antiarrhythmic agent
CHEBI has role CHEBI:38633 sodium channel blockers

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Angina pectoris indication 194828000
Cirrhosis of liver contraindication 19943007 DOID:5082
Torsades de pointes contraindication 31722008
Kidney disease contraindication 90708001 DOID:557
Prolonged QT interval contraindication 111975006
Congenital long QT syndrome contraindication 442917000




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 13.4 acidic
pKa2 6.91 Basic
pKa3 2.91 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Sodium channel protein type 5 subunit alpha Ion channel BLOCKER IC50 5.17 CHEMBL CHEMBL
Potassium voltage-gated channel subfamily H member 2 Ion channel IC50 4.92 WOMBAT-PK
Multidrug resistance protein 1 Transporter WOMBAT-PK
Voltage-gated sodium channel Nav1.5 cardiac isoform Unclassified IC50 5.16 CHEMBL

External reference:

IDSource
4025078 VUID
N0000175343 NUI
D05700 KEGG_DRUG
95635-56-6 SECONDARY_CAS_RN
4025078 VANDF
C0073633 UMLSCUI
CHEBI:87681 CHEBI
CHEMBL1404 ChEMBL_ID
CHEMBL1526084 ChEMBL_ID
CHEMBL537649 ChEMBL_ID
D000069458 MESH_DESCRIPTOR_UI
DB00243 DRUGBANK_ID
56959 PUBCHEM_CID
7291 IUPHAR_LIGAND_ID
5946 INN_ID
A6IEZ5M406 UNII
356778 RXNORM
20936 MMSL
309260 MMSL
75657 MMSL
d05719 MMSL
011195 NDDF
420365007 SNOMEDCT_US
420624001 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Ranolazine Human Prescription Drug Label 1 27241-125 TABLET, EXTENDED RELEASE 500 mg ORAL ANDA 27 sections
Ranolazine Human Prescription Drug Label 1 27241-126 TABLET, EXTENDED RELEASE 1000 mg ORAL ANDA 27 sections
Ranolazine HUMAN PRESCRIPTION DRUG LABEL 1 29300-296 TABLET, FILM COATED, EXTENDED RELEASE 500 mg ORAL ANDA 25 sections
Ranolazine HUMAN PRESCRIPTION DRUG LABEL 1 29300-297 TABLET, FILM COATED, EXTENDED RELEASE 1000 mg ORAL ANDA 25 sections
Ranolazine HUMAN PRESCRIPTION DRUG LABEL 1 31722-668 TABLET, FILM COATED, EXTENDED RELEASE 500 mg ORAL ANDA 29 sections
Ranolazine HUMAN PRESCRIPTION DRUG LABEL 1 31722-669 TABLET, FILM COATED, EXTENDED RELEASE 1000 mg ORAL ANDA 29 sections
Ranolazine HUMAN PRESCRIPTION DRUG LABEL 1 42291-773 TABLET, FILM COATED, EXTENDED RELEASE 500 mg ORAL ANDA 22 sections
Ranolazine HUMAN PRESCRIPTION DRUG LABEL 1 42291-774 TABLET, FILM COATED, EXTENDED RELEASE 1000 mg ORAL ANDA 22 sections
Ranolazine HUMAN PRESCRIPTION DRUG LABEL 1 42385-963 TABLET, FILM COATED, EXTENDED RELEASE 500 mg ORAL ANDA 23 sections
Ranolazine HUMAN PRESCRIPTION DRUG LABEL 1 42385-964 TABLET, FILM COATED, EXTENDED RELEASE 1000 mg ORAL ANDA 23 sections
Ranolazine HUMAN PRESCRIPTION DRUG LABEL 1 42571-324 TABLET, EXTENDED RELEASE 500 mg ORAL ANDA 26 sections
Ranolazine HUMAN PRESCRIPTION DRUG LABEL 1 42571-325 TABLET, EXTENDED RELEASE 1000 mg ORAL ANDA 26 sections
Ranexa HUMAN PRESCRIPTION DRUG LABEL 1 43353-880 TABLET, FILM COATED, EXTENDED RELEASE 500 mg ORAL NDA 28 sections
Ranolazine HUMAN PRESCRIPTION DRUG LABEL 1 45963-418 TABLET, FILM COATED, EXTENDED RELEASE 500 mg ORAL ANDA 27 sections
Ranolazine HUMAN PRESCRIPTION DRUG LABEL 1 45963-418 TABLET, FILM COATED, EXTENDED RELEASE 500 mg ORAL ANDA 27 sections
Ranolazine HUMAN PRESCRIPTION DRUG LABEL 1 45963-419 TABLET, FILM COATED, EXTENDED RELEASE 1000 mg ORAL ANDA 27 sections
Ranolazine HUMAN PRESCRIPTION DRUG LABEL 1 45963-419 TABLET, FILM COATED, EXTENDED RELEASE 1000 mg ORAL ANDA 27 sections
ASPRUZYO SPRINKLE HUMAN PRESCRIPTION DRUG LABEL 1 47335-624 GRANULE 500 mg ORAL NDA 26 sections
ASPRUZYO SPRINKLE HUMAN PRESCRIPTION DRUG LABEL 1 47335-625 GRANULE 1000 mg ORAL NDA 26 sections
RANOLAZINE HUMAN PRESCRIPTION DRUG LABEL 1 50228-423 TABLET, FILM COATED, EXTENDED RELEASE 500 mg ORAL ANDA 27 sections
RANOLAZINE HUMAN PRESCRIPTION DRUG LABEL 1 50228-424 TABLET, FILM COATED, EXTENDED RELEASE 1000 mg ORAL ANDA 27 sections
Ranolazine HUMAN PRESCRIPTION DRUG LABEL 1 50268-722 TABLET, FILM COATED, EXTENDED RELEASE 500 mg ORAL ANDA 25 sections
Ranolazine HUMAN PRESCRIPTION DRUG LABEL 1 50268-723 TABLET, FILM COATED, EXTENDED RELEASE 1000 mg ORAL ANDA 25 sections
RANOLAZINE HUMAN PRESCRIPTION DRUG LABEL 1 51407-225 TABLET, FILM COATED, EXTENDED RELEASE 500 mg ORAL ANDA 27 sections
RANOLAZINE HUMAN PRESCRIPTION DRUG LABEL 1 51407-225 TABLET, FILM COATED, EXTENDED RELEASE 500 mg ORAL ANDA 27 sections
RANOLAZINE HUMAN PRESCRIPTION DRUG LABEL 1 51407-226 TABLET, FILM COATED, EXTENDED RELEASE 1000 mg ORAL ANDA 27 sections
RANOLAZINE HUMAN PRESCRIPTION DRUG LABEL 1 51407-226 TABLET, FILM COATED, EXTENDED RELEASE 1000 mg ORAL ANDA 27 sections
Ranolazine Human Prescription Drug Label 1 59651-009 TABLET, FILM COATED, EXTENDED RELEASE 500 mg ORAL ANDA 27 sections
Ranolazine Human Prescription Drug Label 1 59651-010 TABLET, FILM COATED, EXTENDED RELEASE 1000 mg ORAL ANDA 27 sections
Ranolazine HUMAN PRESCRIPTION DRUG LABEL 1 60687-549 TABLET, EXTENDED RELEASE 500 mg ORAL ANDA 28 sections